Harsch Mutya 4
4 · VYNE Therapeutics Inc. · Filed Jun 2, 2023
Insider Transaction Report
Form 4
Harsch Mutya
CHIEF LEGAL OFFICER AND GC
Transactions
- Award
Common Stock
2023-05-31$3.46/sh+3,664$12,664→ 25,907 total
Footnotes (1)
- [F1]These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2022 and ending on May 31, 2023 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's common stock on December 1, 2022.